Single IV CRISPR Dose Produces ~50% LDL and Triglyceride Reductions at One Year in Early Trial
A single IV dose of CRISPR Therapeutics’ CTX310 produced about 50% average reductions in LDL cholesterol and triglycerides at one year in a small Phase 1a trial.